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Introduction
Acute lung injury (ALI) is a clinical syndrome characterized by impairment in gas exchange and/or lung mechanics that leads to hypoxemia and increased work of breathing (WOB). When respiratory failure occurs, most patients require mechanical ventilation. Th is clinical scenario is related to high morbidity and mortality rates.
Th ere have been large amounts of research on the patho genetic mechanisms of lung injury, which include changes in alveolocapillary permeability, the infl ammatory response, extracellular matrix remodeling and abnormal alveolar micromechanics. In spite of this knowledge, no eff ective therapy, other than treating the initial cause of injury and providing supportive treatment, has been shown to have a signifi cant clinical benefi t. Fortunately, the cause of ALI is known in most cases, so specifi c therapy can be initiated (e.g., antibiotics in sepsis, surgery when appropriate). In other cases, the cause is time-limited, such as in aspiration pneumonitis or polytrauma. However, even in these cases, ALI may persist beyond the initial insult. In this setting, restoration of normal lung structure and function is of paramount importance for survival.
Th ere is increasing evidence of the lung's capacity to repair itself. Th is process involves an interplay between various cellular and molecular mechanisms, including resolution of edema and infl ammation, cell proliferation and tissue remodeling. Moreover, it is possible that some of these mechanisms, activated early in the response to injury, are essential for normal repair later on. With this in mind, timing of a therapeutic intervention becomes a critical issue, as blockade of one mediator may prevent injury when administered early, but also impair the repair phase. Moreover, strategies aimed at promoting repair could represent a new alternative for patients with ALI.
Knowledge of the repair mechanisms could, therefore, be the next step to understanding the lung response to injury. In this review, we will summarize some of these mechanisms and discuss their relevance as potential therapeutic targets in ALI.
An overview of the repair process
Th e lung response to an injurious stimulus involves transduction of the danger signal into a biochemical response. Depending on the cause, there are many pathways that can be activated. For instance, bacterial antigens may trigger an infl ammatory response by activating any of the Toll-like receptors (TLR). Chemical agents induce cell membrane damage and, in some cases, oxidative stress, leading to the activation of a number of intracellular kinases. Mechanical stress, such as positive pressure ventilation, can also precipitate a biological response after a mechanotransduction process [1] .
In addition to exogenous causes, an endogenous system detects tissue and cell damage and triggers the physiological response. Alarmins, a subgroup of molecules of a larger set called DAMPs (damage-associated molecular patterns), lead to this system. Structurally diff erent, these endogenous molecules are released in response to tissue damage by dead cells and local infl ammatory cells (alveolar macrophages in the case of lung), activating and recruiting immune cells through binding to diff erent receptors, such as TLR, interleukin-1 receptor (IL-1R) and RAGE (receptor of advanced glycation end-products) [2] , thereby activating the pro-infl ammatory pathway. Irrespective of the cause, these signals converge in a group of transcription factors (e.g., nuclear factor-kappa B [NF-κB], activator protein [AP]-1), which induce the synthesis of new molecules that ultimately mediate the infl ammatory response to the aggression. Hallmarks of this response are the increased alveolocapillary permeability, which causes a protein-rich edema, the neutrophil infi ltrate (recruited from the circulation in response to chemokines), and the release of a wide variety of mediators, such as cyto-and chemokines, proteases, eicosanoids and growth factors, into the extracellular space. Figure 1 summarizes this process. During this stage, pneumocyte death due to apoptosis (in response to released mediators) and/or necrosis (caused by toxins, proteases...) results in exposure of the basement membrane of the alveolar epithelium.
One of the key steps in the tissue response is the deposition of collagen fi bers at the sites of injury. Similarly to what happens in skin wounds, lung fi bro blasts release procollagen peptides into the extracellular space, in order to create a scar. Th is is probably an attempt to keep the lung structure as intact as possible. So collagen deposition must not be viewed as a late response to abnormal healing, but as an early phenomenon. Some experimental studies corroborate this early onset of collagen deposition [3] . Moreover, patients show an increase in procollagen levels in the fi rst 48 hours after meeting ALI criteria [4] .
Tissue repair involves a variety of mechanisms including edema reabsorption, resolution of infl amma tion and cell proliferation in order to repopulate the alveolar epithelium ( Figure 1c ). Lung edema clearance is a crucial step. It has been documented that mild alveolar injury results in increased alveolar fl uid reabsorption. However, in severe cases, the injured pneumocytes cannot sustain the active transport of ions and water across the epi thelium. Th erefore, cell integrity is essential for edema clearance. Th e molecular mechanisms of ion and water transport in lung exceed the scope of this article, and have been reviewed elsewhere [5] . Regulation of the infl ammatory response is a complex mechanism that requires interplay between several immune mediators [6] . Some anti-infl ammatory cytokines, IL-10 being the most studied, are released even during a pro-infl ammatory response as a negative feedback mechanism. When the pro-infl ammatory pathways are downregulated (i.e., after cessation of the stimulus), these anti-infl ammatory mediators decrease cytokine expression. Apoptosis of infl am matory cells (mainly neutrophils) has also been documented when pro-survival signals, such as granulocyte-colony stimulating factor (G-CSF), disappear. Alveolar macrophages also play a role in this phase engulfi ng death cells.
Finally, the regeneration of the alveolar structure requires the proliferation and diff erentiation of some progenitors into type I pneumocytes ( Figure 2 ). Diff erent growth factors (e.g. epidermic [EGF], keratinocyte [KGF] or hepatic growth factor [HGF]), acting through tyrosinkinase receptors, promote cell proliferation. Th e cell lines implicated in this step are a matter of research, stimulated by the growing interest in stem cells and regenerative medicine [7] . Endogenous progenitor cells include both resident stem cells and bone marrow-derived cells. Regarding the fi rst, type II pneumocytes proliferate after injury and can originate type I cells. Th is has been demonstrated after pneumonectomy, hyperoxia or repeated bleomycin instillation in mice. Moreover, bone marrow-derived stem cells could also participate in alveolar repair, although data on the engraftment and diff erentiation of these cells are more focused on their therapeutic use than to clarify their role in the normal repair process. In addition, other cell types may also play a role in alveolar regeneration. Lung mesenchymal cells are activated after ALI and, in addition to collagen synthesis, they may secrete growth factors and even modu late the immune response by secreting antiinfl ammatory cytokines [8] .
Th e previously formed collagen scar can facilitate cell attachment to keep the alveolar structure. Again, collagen synthesis should be viewed as part of the normal healing process. However, excessive collagen deposition may impair gas exchange and lung mechanics. So, in order to restore normal respiratory function, the previously formed scar must be processed and removed (Figure 1d ). Th is can be carried out by matrix metalloproteinases (MMPs), a family of enzymes that can digest virtually all types of extracellular fi bers [9] . One of the most important sources of MMPs is infl ammatory cells (neutrophils and macrophages contain signifi cant amounts of MMP-8 and MMP-9). Th erefore, it can be hypothesized that the infl ammatory response is important for adequate lung repair, and that MMPs are one of the links between these two phenomena. Th e underlying mechanisms that regulate this step in ALI are unknown, but knowledge of these mechanisms could help clarify why some patients develop a severe fi brotic response, which can cause longterm disabilities.
The special case of repair after ventilator-induced lung injury
Ventilation with high tidal volumes or transpulmonary pressures may cause severe injury to the lungs. In experimental models, there is a clear causality relation ship between ventilatory settings and so-called ventilatorinduced lung injury (VILI). Although this relationship is less clear in patients, especially those with previous ALI, the development of ventilatory strategies aimed to avoid further lung injury has been shown to decrease mortality. Th erefore, although experimental models of VILI cannot be directly extrapolated to critically ill patients, they highlight the mechanisms of injury and repair involved.
A few studies have focused on repair after VILI, giving some insights into this process. Th e fi rst was published by Nin et al. in 2008 [10] . Th ese authors submitted Sprague-Dawley rats to injurious ventilation for one hour, reestablishing spontaneous breathing and letting them recover. Histological studies showed a signifi cant reduction in capillary congestion, interstitial edema, type-I pneumocyte necrosis and hyaline membrane formation after 24 hours of recovery, reaching normality after 72 hours. Infl ammatory markers showed a similar pattern. Aortic vascular and pulmonary microvessel res ponses to acetylcholine and norepinephrine were impaired and returned to normal at 168 and 72 hours respectively. Th is study demonstrated that VILI can revert rapidly after spontaneous breathing is reestablished.
In another study, Gonzalez-Lopez et al. [11] submitted CD1 mice to a combination of two ventilator strategies. One group was ventilated for 90 minutes with high pressures and another group was ventilated with the same strategy followed by up to 4 hours of protective ventilation. Histological score, pulmonary edema, alveolar permeability and tumor necrosis factor (TNF)-α increased during injury and returned to baseline values during repair. Later comparisons of the repair phase showed that survivors had higher pneumocyte proliferation and leukocyte infi ltration and lower alveolar permeability and collagen content than non-survivors. MMP-2 levels were also increased in survivors. Th is MMP improves wound healing in ex vivo models using mice and human alveolar epithelial cell lines. Taken together, these studies suggest that an appropriate infl ammatory response and tissue remodeling are key events during repair.
The role of infl ammation in tissue damage and repair
Infl ammation is necessary for the development of a proper response to the insult, but it can damage the tissue where it takes place. Infl ammation leads initially to an alteration in homeostasis, during which tissue partially sacrifi ces cellular and extracellular matrix integrity and tissue functionality for the benefi t of a quick response. A good example of this compromise is the early recruitment of immune cells to the site of injury. Th e fi rst cells arriving are neutrophils [12] . Representing 70% of total circulating leukocytes, these cells are rapid responders to chemokines, appearing in the lungs a few minutes after initial injury. But this recruitment has a price for lung integrity; after migrating through endothelial cells and before arriving in the alveolar space, leukocytes fi nd the basement membrane, a highly organized extracellular matrix mainly composed of four families of glycoproteins (laminin, collagen type IV isoforms, nidogen and heparan sulfate proteoglycans). Th e basement membrane is actively involved in leukocyte recruitment by its potential to bind and release cytokines and chemotactic factors. Th e only way neutrophils can cross this barrier is by proteolytic degradation [13] , contributing to further damage of lung structure. Once in the lung, the release of a variety of alarmins, free oxygen radicals, leukotrienes, proteases and other pro-infl ammatory molecules maintain the infl ammatory state, thereby contributing to the ALI phase.
Th e role of proteases, especially of MMPs, in the pathogenesis of ALI has been controversial. Extracellular matrix processing releases some bioactive molecules. For example, type I collagen degradation generates an acetylated tripeptide with similar chemotactic activity to IL-8 [14] ; moreover, MMPs process many immune mediators, like pro-and anti-infl ammatory cytokines and chemokines, altering their activity (e.g., IL-1β, transforming growth factor [TGF]β and lipopolysaccharide-induced CXC chemokine [LIX] activation and macrophage infl ammatory protein [MIP]-1α inactivation) and bioavailability (TNF-α and TGFβ release from cell surface and extracellular matrix, respectively) [15] . Th eir ability to regulate the infl ammatory mediators and degrade collagen fi bers also makes MMPs key elements in the later stages of infl ammation, when resolution and repair of the injured tissue are of paramount importance. In a model of liver injury, it has been demonstrated that neutropenic animals develop more severe fi brosis, probably due to the lack of MMPs (released by neutrophils) in the repair phase [16] . A similar dependence between infl ammation and collagenolysis in the lung has not been demonstrated, but these fi ndings warrant more research.
Research on models of lung injury using knock-out mice for single MMPs, such as MMP-2, MMP-3, MMP-7, MMP-8 and MMP-9, has shed some light on this issue. MMP-2 [11] , MMP-7 [17] and MMP-9 [18] have been shown to be involved in alveolar epithelial repair in experi mental models of wound healing. Furthermore, a model of VILI [19] demonstrated that MMP-9 function is worth preserving, given that mice defi cient in this protease had increased levels of lung injury. On the other hand, MMP-3 may be detrimental, as mice lacking this MMP were protected against lung injury caused by administration of nonspecifi c IgG [20] or bleomycin [21] . Regarding MMP-8, this protease has shown diff erent eff ects depending on the experimental model. It has a detrimental role in models of VILI [22] and lung fi brosis, due to IL-10 cleavage [23] . However, this enzyme may be benefi cial after lipopolysaccharide (LPS) or hyperoxia exposition [24] . Moreover, it may have a role in resolution stages of ALI, as it seems to be involved in neutrophil apoptosis through modulation of IL-4 levels [25] .
Th erefore, this complex family serves not only to regulate the infl ux and clearance of leukocytes and the infl ammatory process itself, but also the removal of excess deposits of collagen fi bers released by fi broblasts during ALI. It is becoming clearer that pharmacotherapy should be aimed at blocking specifi c MMPs during the early stages of ALI, in order to avoid destruction of the basement membrane and extracellular matrix caused by their proteolytic action. Although this could have an initial benefi t it may turn detrimental to the repair process if treatment is continued.
Signs of tissue repair in patients
Th e assessment of lung repair in patients could be of great interest because of its prognostic relevance in ALI patients. However, measurement of any mediator involved in tissue repair has one fundamental limitation: If a patient shows high levels of a given marker, it could be due to ongoing repair and, therefore, associated with a good prognosis. However, the same high levels could also be due to massive injury triggering a full-blown response. In this case, the outcome may not be so good.
Collagen levels illustrate this two-sided interpretation of biomarkers. As mentioned before, collagen deposition is an early event during ALI. Increased levels of procollagen in pulmonary edema fl uid may have a prognostic signifi cance in patients with ALI. For instance, Chesnutt et al. [26] reported that a procollagen concentration above 1.75 U/ml had a positive predictive value for death of 0.75. However, a recent article by Quesnel et al. [27] showed that patients with ALI/acute respiratory distress syndrome (ARDS) with fi broblasts in their alveolar fl uid had increased levels of type I procollagen, a decreased pro-infl ammatory response (lower neutrophil count, decreased IL-8 levels), and improved prognosis, suggesting a switch from infl ammation and tissue destruction to alveolar repair.
Research on the prognostic value of MMP-9 has yielded similar confl icting results. Abundance of this protease in bronchoalveolar lavage (BAL) fl uid has been related to a worse outcome. However, MMP-9 has shown a protective role in experimental models of lung injury [19, 28] , and a clinical study demonstrated that this enzyme could have therapeutic value (see below). Finally, the prognostic value of growth factors in ALI was addressed years ago by Verghese et al. [29] . Lower levels of HGF and KGF were found in survivors. Although these mediators promote cell proliferation, diff erentiation and, ultimately, alveolar repair, their presence refl ects a worse outcome. But, as the authors of the article discussed, the increased levels in non-survivors may be a marker of more severe injury.
Collectively, published results suggest that measurement of a single biomarker in patients can be misleading, as it can refl ect both the severity of the injury and the subsequent healing process. An accurate prediction may require complex reasoning that takes into account the initial conditions but also the host's biological response. Th erefore, an approach based on multiple markers could off er an alternative to monitor the course of this disease in patients.
Therapeutic strategies aimed at lung repair
Since identifi cation of the pathways involved in lung injury, most literature has been focused on the use of therapies aimed at reducing ALI by truncating the infl am matory response. Unfortunately, none of these strategies has been successfully applied in the clinical practice. Recently, a signifi cant number of studies have centered their eff orts on enhancing the repair process using diff erent approaches, ranging from the use of biocompatible materials or cells to the therapeutic use of mediators aimed at promoting cell proliferation, migration and diff erentiation. Figure 3 summarizes the diff erent therapeutic targets aimed at favoring lung repair.
In many cases, these studies are still at the in vitro stages, such as the use of vimentin to improve wound repair [30] , or just suggest a possible benefi cial role (e.g., connexins [31] , adrenomedullin [32] or a possible modulation of the transcription factors, FoxM1 and Runx3 [33, 34] ) and need further research to prove their viability in vivo. Improvement of plasma membrane repair is a possible direct treatment. A recent study in an ex vivo model using an amphiphilic macromolecule (Poloxamer 188) with sealing properties showed signs of membrane repair in alveolar resident cells and an improvement in conventional measures of lung injury [35] .
Enhancement of the epithelial repopulation is a promising therapeutic target that could be achieved in diff erent ways. In recent years, therapy using stem cells is gaining considerable interest. It has been demonstrated that these cells are active players in lung repair [36] . In spite of doubts about their safety and the best administration route to improve their engraftment, use of stem cells in animal models has been demonstrated to attenuate damage and fi brosis in lungs challenged with endotoxin [37] . In a recent study, Curley et al. [38] submitted a group of rats to VILI followed by an intravenous injection of mesenchymal stem cells; these animals showed less lung injury and increased levels of the anti-infl ammatory and anti-fi brotic cytokine, IL-10, than did rats who did not receive the stem cells. Th e specifi c mechanisms by which stem cells perform their functions in tissue repair are still under study, but the release of several growth factors and the suppression of pro-infl ammatory cytokines seem to be involved.
An alternative approach is the therapeutic use of exogenous growth factors to induce the proliferation of endogenous stem cells. Among these factors, EGF, KGF and HGF have been the most studied. All of them are mitogens in type II pneumocytes, and act synergistically to mediate their maturation and increase surfactant synthesis [8] . EGF had benefi cial eff ects in an animal model of ALI [39] , and inhibition of EGF receptor had a González-López and Albaiceta Critical Care 2012, 16:209 http://ccforum.com/content/16/2/209 detrimental eff ect during airway epithelium repair [40] . KGF has been linked to upregulation of anti-infl am matory cytokines and modulation of epithelial cell migration [41] . In the same way, HGF attenuates infl ammation and showed antifi brotic eff ects in a murine model of bleomycin-induced fi brosis [42] . Vascular endothelial growth factor (VEGF) could also have a therapeutic eff ect by its ability to repair damaged endothelium, therefore helping in clearance of lung edema, but animal models have shown disappointing results [43] .
Finally, manipulation of tissue remodeling could improve the outcome of ALI patients by favoring reepithelization or avoiding fi brosis. Th e use of steroids in ALI has yielded confl icting results, depending on the time of application. Th ese discrepancies can be explained if one takes into account the benefi cial eff ects of infl ammation during the repair phase discussed earlier. However, no study has specifi cally addressed the eff ects of steroids during lung repair.
MMPs are alternative targets to promote repair. Nonselective MMP inhibitors are available, but the lack of specifi city could limit their benefi ts and none of them has been tested in ALI. Selective blockade or stimulation (depending on the role of the MMP and timing) could be a more promising approach. One of the fi rst examples that has arrived in human trials is the use of beta-2 adrenergic receptor agonists. Intravenous administration of salbutamol decreased the duration and severity of lung injury by reducing lung edema in patients with ARDS [44] . Th is fi nding was associated with an upregulation of MMP-9 [18] and, therefore, with better alveolar epithelial repair [45] . Nevertheless, the route of administration could be relevant, as a recent trial has concluded that patients with ALI treated with inhaled salbutamol show no signifi cant improvement in clinical outcomes [46] . On the other hand, blockade of MMP-8 has shown benefi cial eff ects in experimental models of lung injury [22] , including decreased lung fi brosis after bleomycin administration [23] . However, no clinical study aimed at modulating this protease has yet been proposed.
Conclusion
Th e lungs have a substantial potential for recovery after ALI. Of note, the mechanisms that can cause tissue disruption in the early phase also contribute to its repair later on, infl ammation and matrix remodeling being paradigmatic examples. Th erefore, therapies that disrupt these pathways, such as MMP inhibition, may have a prophylactic value, but their application at a later phase could be detrimental. Knowledge of the mediators involved in tissue repair could lead to new therapeutic strategies being applied after the initial insult has been controlled. Growth factors, exogenous stem cells (including type II pneumocytes) or drugs that promote matrix remodeling could be new alternatives to improve the prognosis of patients with ALI.
